fda compounding glp-1 enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Out of Shortage, Into Controversy:

42 Compared to GLP-1, exenatide has nine extra residues in the C-terminal, which constitute a so-called Trp-cage structure, folding and shielding the Trp 25 indole ring from solvent exposure

Tirzepatide is a medication that works on two natural hormones in the body, GIP and GLP-1, which help control blood sugar and appetite

4Moving Biotech and Sorbonne University own 2 patents for method of use of GLP1 analogs in the treatment of osteoarthritis (PCT/FR2013/051998 and PCT/IB2018 Additional information Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Novo Nordisk, the Danish pharma company behind several GLP-1RA drugs (including Ozempic/Wegovy and Saxenda) grew its sales by over 30% in 2023, and its share price rose by over 70% in the last year, making it the most valuable European company by market capitalization

10.1111/dom.16364 101 TianS.LeiY.ZhaoF.CheJ.WuY.LeiP.et al (2024)

The Loss of Exclusivity (LOE) of semaglutide in China, Brazil, Canada and India in 2026 will result in the availability of cheaper generics in these countries (and possibly neighbouring countries via parallel import)